BPC-157
Body Protection Compound-157 | Pentadecapeptide
Community Research
Join others researching BPC-157 — share findings, ask questions, and learn from real experiences
Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood vessel formation, enhances collagen synthesis, modulates growth factor expression, and protects against tissue damage through localized or systemic delivery.
Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways.
Molecular Data
Glycine
Position 1
Lysine
Position 2
Proline
Position 3
Position 4
Position 5
Position 6
Position 7
Position 8
Alanine
Position 9
Aspartic Acid
Position 10
Position 11
Position 12
Position 13
Leucine
Position 14
Valine
Position 15
Research Indications
Accelerated tendon-to-bone healing with improved biomechanical properties; most effective with localized injection.
Enhanced healing and reduced recovery following crush injuries and surgical procedures with direct tissue targeting.
Promotes blood vessel formation and improves vascularization through localized delivery.
Protective effects against neurotoxic agents and ischemic brain injury models.
Improved functional recovery and reduced tissue damage in spinal cord injury studies.
Enhanced peripheral nerve regeneration and functional recovery after injury.
Protective effects against gastric and duodenal ulcers through cytoprotective mechanisms.
Acceleration of intestinal healing with reduced inflammatory markers in IBD models.
Enhanced mucosal barrier function and accelerated epithelial regeneration.
Dosing Protocols
Most effective for localized healing when injected near injury site. Subcutaneous injection preferred for targeted tissue repair.
Tendon/Joint healing
250-500 mcg
1-2x daily
SubQ near injury
Serious injury
500-1000 mcg
2x daily
General healing
SubQ or IM
Maintenance
250 mcg
1x daily
SubQ
Reconstitution Instructions
Bacteriostatic water (BAC)
Insulin syringes (0.5-1 mL)
Alcohol swabs
Peptide vial
Sterile work surface
1 Clean work area and hands thoroughly
2 Calculate required BAC water volume using calculator
3 Draw BAC water into syringe
4 Inject slowly down vial side (not directly onto powder)
5 Gently swirl until dissolved (never shake)
6 Store in refrigerator, use within 28 days
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Stop Signs - Discontinue if:
Persistent injection site reactions or infection signs
Unusual swelling or rash around injection area
Severe headaches or dizziness
Allergic reactions
Persistent or worsening digestive issues
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Quality Checklist
Good Signs
White, fluffy lyophilized powder (cake) filling vial bottom
Crystal clear solution after reconstitution with no particles
Intact vacuum seal on vial
Warning Signs
Slight clumping that dissolves with gentle swirling (acceptable from shipping)
Bad Signs
Collapsed, melted, or powder stuck to vial sides (heat exposure)
Cloudy solution, particles, or precipitates after reconstitution
Discoloration of powder
Frequently Asked Questions
Should I inject BPC-157 near the injury site or take it systemically?
Localized injection near the injury site is most effective for direct tissue targeting and healing. However, BPC-157 has systemic effects, so oral administration (on empty stomach) or distant SubQ injection provides whole-body benefits. For serious tendon/joint injuries, localized injection + oral combination protocol maximizes effects.
Can I use BPC-157 with NSAIDs like ibuprofen?
BPC-157 rescued NSAID-cytotoxicity by stabilizing intestinal permeability and protecting mucosal barrier function in research. This suggests potential synergy—BPC-157 may mitigate NSAID side effects while NSAIDs reduce acute inflammation. However, clinical data on combination timing and dosing doesn't exist.
How long can I use BPC-157 or does it require cycling?
BPC-157 is typically used for 4-12 weeks depending on injury severity. Its short half-life (<30 minutes) and safety profile in preclinical studies suggest longer use is likely safe, but formal long-term human data doesn't exist. Cycling 1-2 weeks on/off may prevent adaptation, though continuous use hasn't shown problems.
Why must I avoid BPC-157 if I have cancer or am on blood thinners?
BPC-157 promotes angiogenesis (new blood vessel formation), which theoretically could support tumor blood supply. For cancer patients, this creates potential risk despite no direct clinical data. Blood thinners combined with pro-angiogenic effects increase bleeding risk, warranting medical supervision before use.
References
Superior tendon healing with improved biomechanical properties (increased load of failure and Young's modulus), enhanced tendon-to-bone integration, and stimulated tendocyte growth in rat models.
Accelerated quadriceps healing over 72-day period with improved biomechanics, walking recovery, muscle fiber regeneration with desmin positivity, and attenuated atrophy in rat models.
Significant functional recovery with improved motor function, resolved spasticity by day 15, and counteracted axonal necrosis, demyelination, and cyst formation across all stages of secondary injury.
Cytoprotective effects against NSAID-induced gastric and intestinal damage by stabilizing intestinal permeability and protecting mucosal barrier function across multiple epithelia.
Pro-angiogenic effects via VEGFR2-Akt-eNOS signaling pathway activation, increased vessel density in vivo and in vitro, and accelerated blood flow recovery in ischemic rat hind limb model.
Well tolerated in mice, rats, rabbits, and dogs with no serious toxicity in single-dose, repeated-dose, local tolerance, genetic, or embryo-fetal toxicity studies.
Pilot human trial in 12 women (ages 39-76) with interstitial cystitis showed BPC-157 as a potential treatment for this disabling condition with no effective existing therapies.
First human IV safety data: infusions of up to 20 mg BPC-157 in 2 healthy adults showed no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers.
Related Peptides
Complementary healing mechanisms; often used together in the Wolverine Stack.
No known negative interactions.
BPC-157 increases GH receptor expression, amplifying growth hormone benefits.
No known interactions; different mechanisms and receptor targets.
Safe combination; different pathways. Often combined in regenerative protocols.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.